About EAB-277® / PCSO-524®

What is PCSO-524^®?

Antinol^® (PCSO-524^®) is a natural anti-inflammatory supplement for the veterinary market containing a patented lipid extract isolated from the New Zealand green-lipped mussel, Perna canaliculus. Antinol^® contains PCSO-524^® in combination with olive oil, and a small amount of vitamin E added as an antioxidant. Early in vitro and in vivo research indicated significant anti-inflammatory properties. However, this research also revealed inconsistencies in the results due to the poor stabilisation of the lipids. Subsequent research and further development culminated in the stabilised patented lipid extract PCSO-524^® found in Antinol^®.

What is EAB-277^®?

The active ingredient in this advanced formulation of EAB 277™ is the blend of New Zealand green mussel oil and high phospholipid krill oil. EAB 277™ helps promote efficiency in absorption with the pet’s body and packed with high nutritional value. It contains more than 90 free fatty acids that are complete with omega-3s , including DHA, EPA and ETA .

The synergistic advanced formula

EAB 277™ is the product of years of ongoing scientific research. To study, research and develop for the best effectiveness of the synergy of the active ingredients. The perfect combination of 30 mg of Perna canaliculus (New Zealand green mussel) oil and 20 mg of high phospholipid krill oil has been proven in laboratory tests it is more effective than using any type of fat alone.

The blend contains a unique combination of free fatty acids, sterol esters, polar lipids, and carotenoids, and has been shown to be a 5-lipoxygenase (LOX)¹ and cyclooxygenase 2 (COX-2) modulator ² providing a potent anti-inflammatory effect ^3-6. The majority of the research using EAB 277™ has been in support of its anti-inflammatory activity, particularly in arthritis, where it has been compared to non-steroidal anti-inflammatory drugs (NSAIDs) in several animal clinical trials.

The manufacture and extraction process of EAB 277™ has been developed over many years and is covered by several international patents. The patented process involves extracting the oil from green lipped mussels which are first stabilised and freeze-dried.
The extraction is undertaken using supercritical fluid extraction (SFE) technology which uses liquid carbon dioxide (CO₂) as a solvent. CO₂ is an ideal solvent as it becomes liquid under increased pressure and after extracting the oil the pressure is raised, and the CO₂ turns back into a gas leaving the extract intact.

EAB 277™ is produced in Nelson, New Zealand where the green-lipped mussels are farmed in pristine waters. The stabilisation process and freeze drying of the mussels is conducted by Pharmalink International (PIL) shareholder and manufacturing partner MacLab and the extraction is completed in a state of the art facility owned by Pharmalink Extracts Limited.

The patented EAB 277™ extract is sold in more than 40 countries around the world in soft-gel capsules, blister packed in aluminium foil, which are encapsulated and packaged by a number of GMP-approved facilities around the globe.

Unique features of Antinol^® / Point of difference

The unique lipid extract within Antinol^® is different in structure compared with other marine oils (i.e. fish oils) in the chemical bonding of the omega fatty acids and incorporates a wide diversity of lipid classes.

There are over 91 individual fatty acids reported within the lipid extract with only 16 at concentrations greater than 1% of the total fatty acids ⁷
Specific fractionation studies have shown a range of anti-inflammatory compounds found within the EAB 277™ matrix ^{8, 9}
The primary anti-inflammatory component of the lipid mix has not been identified but has been determined to be more complex than just the DHA/EPA component
The anti-inflammatory action of the whole extract (EAB 277^™) is more effective than the sum of its parts.

Therapeutic uses

The primary recommendation for Antinol^® use is for arthritis and other inflammatory conditions.

The Importance of the Stabilised Extract

The patented extraction process has been refined over a number of years and produces an extract with consistent anti-inflammatory results due to the stable, consistent nature of the product. The early research informed us that a non-stabilised mussel powder could not consistently produce positive results, crude extracts were vulnerable to chemical change over time providing variable or unpredictable results.

The Importance of the 2 Synergistic Extracts

Antinol^® EAB 277™ has been clinically proven in veterinary medicine to significantly improve the health and wellbeing of pets in 90% of sick animals with more than 10+ supporting scientific findings Clinical studies conducted with veterinarians. And there are also research papers that have been published internationally. Including going to academic journals that have been reviewed by a panel of experts. (peer-reviewed study)

The Effective Synergistic Combination of 2 Marine Lipids

One of the main active ingredients in EAB-277® and PCSO-524® is New Zealand green mussel extract. The New Zealand green-lipped mussels are subjected to a stabilization and freeze-drying process prior to the proprietary liquid extraction techniques.

Most green-lipped mussel (GLM) extracts on the market are not stabilised extracts and therefore may be vulnerable to change over time.

No other product has the stabilisation process used by PIL to manufacture Antinol^®.

Comparison of different mussel extracts for their anti-inflammatory activity reveal a wide variability in effectiveness, showing the stabilised lipid extract to be far superior.

Ready to level up your gaming? Unlock the potential of your account with a qbet bonus and enjoy extra perks right from the start. By using a qbet bonus code, you’ll give yourself a head start, whether you prefer high-energy slqbet bonus codeots or immersive live casino games. It’s the perfect way to get more value from your playtime. Why settle for less when you can start with more?

Compared to Non-stabilised GLM Extract

Comparison of similar clinical trials using a non-stabilised mussel extract to Antinol^® for treatment of osteoarthritis in dogs have shown stronger outcomes for Antinol^®

Compared to Counter Treatment

Comparison of PCSO-524^® to other available over the counter treatments for osteoarthritis in a rat trial, place it in the top two products of a group of 27, with the other top product being the stabilised GLM powder from which Antinol^® is made

Compared to other Nutraceuticals

Clinical trials have also demonstrated the superiority of Antinol^® to other nutraceuticals commonly used for arthritis or joint disease in dogs.

These include glucosamine, chondroitin, and avocado soy-bean unsaponifiables.

Compared to Non-stabilised GLM Extract

Comparison of similar clinical trials using a non-stabilised mussel extract to EAB 277™ for treatment of osteoarthritis in dogs have shown stronger outcomes for EAB 277™

Anti-inflammatory Activity

There are two major inflammation pathways relevant to pain in osteoarthritis (OA).

These are the cyclooxygenase pathways (COX-1 and COX-2) and the lipoxygenase pathway, which can be separated into 3-arms (15-LOX, 12-LOX and 5-LOX) of which the 5-LOX pathway is the best studied for OA.

COX and LOX pathways

COX and LOX pathways are inflammatory cascades that are initiated in ordinary cells from the lipid content that makes up the cellular membranes.

Initiation and control of the inflammatory process are complex and governed by an array of biomolecular mechanisms.

One important pro-inflammatory mechanism is associated closely with the cell-membrane-bound fatty acid arachidonic acid, which becomes converted into other compounds in the body that are potent pro-inflammatory substances.

The composition of the cellular fatty acids within cells is an area of particular interest when looking at the effects of dietary or supplemental fatty acids in the body (i.e. PCSO-524^®).

The composition can directly influence inflammatory processes in the body. In fact, research is now suggesting that fatty acids within the diet can alter OA risk and severity.

Working in conjunction with NSAIDs, or to replace NSAID use

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs for arthritis conditions in humans and animals.

One of their main mechanisms of action is inhibition of the COX enzyme (shown with its link to the inflammatory mediators produced from arachidonic acid in Figure 1), which in turn, inhibits the production of prostaglandins, especially PGE2, one of the key inflammatory mediators known to cause inflammation and therefore pain, which is strongly implicated in OA.

NSAIDs are also well known for their potential gastrointestinal side effects, including the development of gastric ulceration.

A review of the use of NSAIDs in dogs notes that monitoring them for gastric ulceration is difficult as there are no practical screening tests to detect early signs of gastric injury, with clinicians needing to be vigilant for signs of injury.

                    Executive Summary

for EAB-277®
and PCSO-524®
                  

EAB 277™

Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: A prospective, block-randomized, double-blinded, placebo-controlled clinical trial

Front. Vet. Sci., 01 February 2023 Sec. Veterinary Surgery and Anesthesiology Volume 10 - 2023 | https://doi.org/10.3389/fvets.2023.1033188

Authors:

Naruepon Kampa, Duangdaun Kaenkangploo, Supranee Jitpean, Thanikul Srithunyarat, Suvaluk Seesupa, Somphong Hoisang, Karn Yongvanit, Phanthit Kamlangchai, Pongsatorn Tuchpramuk, B. Duncan X. Lascelles

VIEW

EAB 277™Respiratory

Polyunsaturated Fatty Acid EAB-277® Supplementation Improved Heart Rate Variability and Clinical Signs in Tracheal Collapse Dogs

Front. Vet. Sci., 14 July 2022

Authors:

Raktham Mektrirat, Thareerat Rueangsri, Waraporn Keeratichandacha, Sasiwimon Soonsawat, Chavalit Boonyapakorn, Wanpitak Pongkan

VIEW

The Effectiveness of Marine Based Fatty Acid Compound (PCSO-524) and Firocoxib in the Treatment of Canine Osteoarthritis

BMC Veterinary Research (2019) 15:349

Authors:

Monchanok Vijarnsorn, Irin Kwananocha, Narudee Kashemsant, Thitichai Jarudecha, Chalermpol Lekcharoensuk, Bruno Peirone, Brian S. Beale, B. Duncan X. Lascelles

VIEW

The Effectiveness of Marine Based Fatty Acid Compound (PCSO-524) Alone and Combined with Firocoxib in the Treatment of Canine Osteoarthritis

Veterinary Orthopedic Society Conference 2018 Poster Presentation.
(VOS conference, March 2018)

Authors:

Brian S. Beale, Monchanok Vijarnsorn, Irin Kwananocha, Alois Nečas, B. Duncan X. Lascelles

VIEW

Skin

Clinical study of PCSO-524 (ANTINOL™) as neutraceutical in canine allergic skin disease

Oral Presentation at The World Veterinary Congress WVAC 2018

Authors:

Chaiyot Tanrattana

VIEW

Effectiveness of Disease Modifying Osteoarthritis Agents and Carprofen for Treatment of Canine Osteoarthritis

Thai J Vet Med. 2016. 46(3): 363-371.

Authors:

Irin Kwananocha, Monchanok Vijarnsorn, Narudee Kashemsant, Chalermpol Lekcharoensuk

VIEW

The Effectiveness of Marine Based Fatty Acid Compound and NSAIDs for the Treatment of Canine Osteoarthritis: a preliminary study

WSAVA Congress 2015

Authors:

Irin Kwananocha, Monchanok Vijarnsorn, Narudee Kashemsant, Chalermpol Lekcharoensuk

VIEW

Bone & Joint Bone & Joint Bone & Joint Bone & Joint Bone & Joint Bone & Joint Bone & Joint Bone & Joint

Effect of PCSO-524 on OA Biomarkers and Weight Bearing Properties in Canine Shoulder and Coxofemeral Osteoarthritis

Thai Journal Vet Med. 2015

Authors:

Kumpanart Sundaravibhata, Natwadee Mongkhon, Korakot Nganvongpanit, Prachya Kongtawelert

VIEW

Application of the Polyunsaturated fatty acid compound PCSO-524 in the post operative recovery of dogs that have had stifle surgery

WSAVA FASAVA Congress 2013
World Small Animal Veterinary Assoc.
38th Annual Congress 6-9 March 2013, Auckland, New Zealand

Authors:

Kumpanart Sundaravibhata, Natwadee Mongkhon, Prach Maihasap

VIEW

Dog Dog Dog Dog Dog Dog Dog Dog Dog Dog

The Preliminary study of the Clinical outcome of using the PCSO-524 polyunsaturated fatty acid compound (Antinol) in the treatment of Canine Osteoarthritis and degenerative spinal diseases

Thai Journal Vet Med. 2012. 42(3): 311-317.

Authors:

Natwadee Mongkhon, Kumpanart Sundaravibhata

VIEW

Reference
Journals & Publications

PCSO-524® Reference

1. Dugas B. Lyprinol inhibits LTB4 production by human monocytes. Allerg Immunol, 2000. 32(7): p. 284-289.

2. McPhee S, Hodges LD, Wright PFA, Wynne PM, Kalafatis N, Harney DW, et al. Anti-cyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel, Perna canaliculus. Comp Biochem Physiol B: Biochem Mol Biol, 2007. 146(3): p. 346-356.

3. Lee CH, Butt YKC, Wong MS, Lo SCL. A lipid extract of Perna canaliculus affects the expression of pro-inflammatory cytokines in a rat adjuvant-induced arthritis model. Eur Ann Allergy Clin Immunol, 2008. 40(4): p. 148-153.

4. Singh M, Hodges LD, Wright PFA, Cheah DMY, Wynne PM, Kalafatis N, et al. The CO2-SFE crude lipid extract and the free fatty acid

extract from Perna canaliculus have anti-inflammatory effects on adjuvant-induced arthritis in rats. Comp Biochem Physiol B: Biochem Mol Biol, 2008. 149(2): p. 251-258.

5. Whitehouse MW, Macrides TA, Kalafatis N, Betts WH, Haynes DR, Broadbent J. Anti-inflammatory activity of a lipid fraction (Lyprinol) from the NZ green-lipped mussel. Inflammopharmacology, 1997. 5(3): p. 237-246.

6. Treschow AP, Hodges LD, Wright PFA, Wynne PM, Kalafatis N, Macrides TA. Novel anti-inflammatory n-3 PUFAs from the New Zealand green-lipped mussel, Perna canaliculus. Comp Biochem Physiol B: Biochem Mol Biol, 2007. 147(4): p. 645-656.

7. Wolyniak CJ, Brenna JT, Murphy KJ, Sinclair AJ. Gas chromatography-chemical ionization-mass spectrometric fatty acid analysis of a commercial supercritical carbon dioxide lipid extract from New Zealand green-lipped mussel (Perna canaliculus). Lipids, 2005. 40(4):p. 355-360.

8. McPhee S, Kalafatis N, Wright P, Macrides T, (eds). The marine oil Lyprinol®, is a substrate for the 5-lipoxygenase enzyme in porcine neutrophils. in Proc Aust Soc Clin Exp Pharmacol Toxicol, 2001. 9: 95.

9. Whitehouse M, Roberts M, Brooks P. Over the counter (OTC) oral remedies for arthritis and rheumatism: How effective are they? Inflammopharmacology, 1999. 7(2): p. 89-105.

10. Rialland P, Bichot S, Lussier B, Moreau M, Beaudry F, del Castillo JRE, et al. Effect of a diet enriched with green-lipped mussel on pain behavior and functioning in dogs with clinical osteoarthritis. Can J Vet Res, 2013. 77(1): p. 66-74.

11. Kwananocha I, Vijarnsorn M, Kashemsant N, Lekcharoensuk C. Effectiveness of disease modifying osteoarthritis agents and carprofen for treatment of canine osteoarthritis. Thai J Vet Med, 2016. 46(3): p. 363-371.

12. Soontornvipart K, Mongkhon N, Nganvongpanit K, Kongtawelert P. Effect of PCSO-524 on OA biomarkers and weight-bearing properties in canine shoulder and coxofemeral osteoarthritis. Thai J Vet Med, 2015. 45(2): p. 157-165.

13. Sundaravibhata K, Mongkhon N, Meahasab P. Application of the polyunsaturated fatty acid compound PCSO-524 in the postoperative recovery of dogs that have had stifle surgery. WSAVA 38th Ann Cong. Auckland, New Zealand 2013.

14. Sekar S, Crawford R, Xiao Y, Prasadam I. Dietary fats and osteoarthritis: Insights, evidences, and new horizons. J Cell Biochem, 2017.118(3): p. 453-463.

15. Miles EA, Calder PC. Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Br J Nutr, 2012. 107 Suppl 2: p. S171-S184.

16. Bacchi S, Palumba P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: A review. Antiinflamm Antiallergy Agents Med Chem, 2012. 11(1): p. 52-64.

17. Lascelles BD, McFarland JM, Swann H. Guidelines for safe and effective use of NSAIDs in dogs. Vet Therap, 2005. 6(3): p. 237-51.

18. Whitehouse MW, Butters DE. Combination anti-inflammatory therapy: Synergism in rats of NSAIDs/corticosteroids with some herbal/animal products. Inflammopharmacology, 2003. 11(4-6): p. 453-464.

19. Mongkon N, Soontornvipart K. Preliminary study of the clinical outcome of using PCSO-524 polyunsaturated fatty acid compound in the treatment of canine osteoarthritis and degenerative spinal diseases. Thai J Vet Med, 2012. 42(3): p. 311-317.

20. Kongwut S, Soontornvipart K, Sarikaphuti M, Makoom P, Nganvongpanit K. Effects of serum IL-1beta of PCSO-524 and Firocoxib in dogs undergoing medial patellar luxation repair. Thai J Vet Med, 2015. 45(4): p. 639-643.

21. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood, 2011. 117(14): p. 3720-3732.

22. van Dalen SC, Blom AB, Slöetjes AW, Helsen MM, Roth J, Vogl T, et al. Interleukin-1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis. Osteoarthritis Cartilage, 2017. 25(3): p. 385-396.

23. Jamikorn U, Yibchok-anun S. Effects of dietary polyunsaturated fatty acid supplement on healthy Beagle dogs. Thai J Vet Med, 2014.44(4): p. 505-511.

24. Szechinski J, Zawadzki M. Measurement of pain relief resulting from the administration of Perna canaliculus lipid complex PCSO-524™ as compared to fish oil for treating patients who suffer from osteoarthritis of knee and/or hip joints. Rheumatologia, 2011. 49(4): p. 244-252.

25. Zawadzki M, Janosch C, Szechinski J. Perna canaliculus lipid complex PCSO-524™ demonstrated pain relief for osteoarthritis patients benchmarked against fish oil, a randomized trial, without placebo control. Mar Drugs, 2013. 11(6): p. 1920-1935.

26. Cho SH, Jung YB, Seong SC, Park HB, Byun KY, Lee DC, et al. Clinical efficacy and safety of Lyprinol, a patented extract from New

Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: A multicenter 2-month clinical trial. Eur Ann Allergy Clin Immunol, 2003. 35(6): p. 212-216.

27. Gibson SLM, Gibson RG. The treatment of arthritis with a lipid extract of Perna canaliculus: A randomized trial. Complement Ther Med, 1998. 6(3): p. 122-126.

28. Puente R, Illnait J, Mas R, Mendoza S, Carbajal D, Fernández J, et al. Effects of D-002, a mixture of beeswax alcohols, co-administered with green-lipped mussel extract, on osteoarthritis symptoms. Int J Pharm Sci Rev Res, 2014. 27(1): p. 209-216.

29. Lau CS, Chiu PKY, Chu EMY, Cheng IYW, Tang WM, Man RYK, et al. Treatment of knee osteoarthritis with Lyprinol, a lipid extract of the green-lipped mussel: A double-blind placebo-controlled study. Prog Nutr, 2004. 6(1): p. 17-31.

30. Audeval B, Bouchacourt P. Double-blind trial against placebo of extract of Perna canaliculus (green-lipped mussel) in osteoarthritis of the knee. Gaz Med Fr, 1986. 93: p. 111-116.

31. Gibson RG, Gibson SL, Conway V, Chappell D. Perna canaliculus in the treatment of arthritis. Practitioner, 1980. 224: p. 955-960.

32. Gandek B. Measurement properties of the Western Ontario and McMaster Universities Osteoarthritis Index: A systematic review. Arthritis Care Res, 2015. 67(2): p. 216-229.

33. Lau CS, Chiu PKY, Chu EMY, Cheng IYW, Tang WM, Man RYK, et al. Treatment of knee osteoarthritis with Lyprinol, a lipid extract of the green-lipped mussel: A double-blind placebo-controlled study. Prog Nutr, 2004. 6(1): p. 17-31.

34. Lee CH, Butt YKC, Wong MS, Lo SCL. Differential protein expression induced by a lipid extract of Perna canaliculus in splenocytes of rats with adjuvant-induced arthritis. Inflammopharmacology, 2008. 16(4): p. 188-194.

35. Lee C-H, Lum JH-K, Ng CK-C, McKay J, Butt YK-C, Wong M-S, et al. Pain controlling and cytokine-regulating effects of Lyprinol, a lipid extract of Perna canaliculus, in a rat adjuvant-induced arthritis model. Evid Based Complement Alternat Med, 2009. 6(2): p. 239-245.

36. Wakimoto T, Kondo H, Nii H, Kimura K, Egami Y, Oka Y, et al. Furan fatty acid as an anti-inflammatory component from the greenlipped mussel Perna canaliculus. Proc Natl Acad Sci, 2011. 108(42): p. 17533-17537.

37. Pearson W, Orth MW, Karrow NA, Maclusky NJ, Lindinger MI. Anti-inflammatory and chondroprotective effects of nutraceuticals from Sasha’s Blend in a cartilage explant model of inflammation. Mol Nutr Food Res, 2007. 51(8): p. 1020-1030.

38. Yanez JA, Remsberg CM, Vega-Villa KR, Miranda ND, Navas J, Ohgami Y, et al. Pharmacological evaluation of Glyco-Flex® III and its constituents on canine chondrocytes. J Med Sci, 2008. 8: p. 98-101.

39. Beale S. Brian, Vijarnsorn Monchanok, Kawananocha Irin, Necas Alois, Lascelles X. B.Duncan. The Effectiveness of Marine Based Fatty Acid compound (PCSO-524) Alone and Combined with Firocoxib in the treatment of Canine Osteoarthritis. Veterinary Orthopaedic Society Conference. March 2018.

40. Vijarnson Monchanok, Kwananocha Irin, Kashemsant Naruedee, Jarudecha Thitichai, et al. Effectiveness of Marine Based Fatty Acid compound (PCSO-524) and Firocoxib in the treatment of Canine Osteoarthritis.BMC Veterinary Research 2019 OCT 17;15(1):349

41. Kwananocha Irin. Journal of Thai Veterinary Practitioners. 2020 (Synopsis)

42. Rungnirundon Teerapat, Senarut Napaporn. PCSO-524 (Antinol®) Use in Fighting Cocks for Treatment of Chronic Pododermatitis. Journal of Thai Veterinary Practitioners.2020 (Synopsis)

43. Nishida Koji.PCSO-524 Report Clinical Results of Nineteen Dogs with Tracheal Collapse that received PCSO-524,a Lipid Extract of New Zealand Green Lipped Mussel(Perna canaliculus). Journal of Modern Veterinary Medicine (MVM) Vol.24 No.163 (2016)

44. Tanrattana Chaiyot, Panitarnangit Sivavatchr, Moolasatsathorn Warawadee.Clinical Study of PCSO-524 (Antinol) as neutraceutical in Canine allergic skin disease. World Veterinary Association Congress 2018

_________________________________

EAB-277® Reference

1. Franklin SP, Park RD, Egger EL. Metacarpophalangeal and metatarsophalangeal osteoarthritis in 49 dogs. J Am Anim Hosp Assoc. (2009) 45:112–7. doi: 10.5326/0450112

2. Rychel JK. Diagnosis and treatment of osteoarthritis. Top Companion Anim Med. (2010) 25:20–5. doi: 10.1053/j.tcam.2009.10.005

3. Johnston SA. Osteoarthritis. Joint anatomy, physiology, and pathobiology. Vet Clin North Am Small Anim Pract. (1997) 27:699–723. doi: 10.1016/S0195-5616(97)50076-3

4. Wright A, Amodie DM, Cernicchiaro N, Lascelles BDX, Pavlock AM, Roberts C, et al. Identification of canine osteoarthritis using an owner-reported questionnaire and treatment monitoring using functional mobility tests. J Small Anim Pract. (2022) 63:609–18. doi: 10.1111/jsap.13500

5. Moreau M, Dupuis J, Bonneau NH, Desnoyers M. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec. (2003) 152:323–9. doi: 10.1136/vr.152.11.323

6. Sanderson RO, Beata C, Flipo RM, Genevois JP, Macias C, Tacke S, et al. Systematic review of the management of canine osteoarthritis. Vet Rec. (2009) 164:418– 24.doi: 10.1136/vr.164.14.418

7. Edamura K, King JN, Seewald W, Sakakibara N, Okumura M. Comparison of oral robenacoxib and carprofen for the treatment of osteoarthritis in dogs: a randomized clinical trial. J Vet Med Sci. (2012) 74:1121–31. doi: 10.1292/jvms.11-0529

8. Vasseur PB, Johnson AL, Budsberg SC, Lincoln JD, Toombs JP, Whitehair JG, et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal antiinflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc. (1995) 206:807–11.

9. Mansa S, Palmer E, Grondahl C, Lonaas L, Nyman G. Long-term treatment with carprofen of 805 dogs with osteoarthritis. Vet Rec. (2007) 160:427–30. doi: 10.1136/vr.160.13.427

10. Brown DC, Boston RC, Coyne JC, Farrar JT. Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc. (2008) 233:1278–83. doi: 10.2460/javma.233.8.127

11. Bhathal A, Spryszak M, Louizos C, Frankel G. Glucosamine and chondroitin use in canines for osteoarthritis: a review. Open Vet J. (2017) 7:36–49. doi: 10.4314/ovj.v7i1.6

12. Monteiro-Steagall BP, Steagall PV, Lascelles BD. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med. (2013) 27:1011–9. doi: 10.1111/jvim.12127

13. Aragon CL, Hofmeister EH, Budsberg SC. Systematic review of clinical trials of treatments for osteoarthritis in dogs. J Am Vet Med Assoc. (2007) 230:514– 21. doi:10.2460/javma.230.4.514

14. Beale BS. Use of nutraceuticals and chondroprotectants in osteoarthritic dogs and cats. Vet Clin North Am Small Anim Pract. (2004) 34:271–89, viii. doi: 10.1016/j.cvsm.2003.09.008

15. McCarthy G, O’Donovan J, Jones B, McAllister H, Seed M, Mooney C. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Vet J. (2007) 174:54– 61. doi: 10.1016/j.tvjl.2006.02.015

16. Gupta RC, Canerdy TD, Lindley J, Konemann M, Minniear J, Carroll BA, et al. Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. J Anim Physiol Anim Nutr. (2012) 96:770–7. doi: 10.1111/j.1439-0396.2011.01166.x

17. Scott RM, Evans R, Conzemius MG. Efficacy of an oral nutraceutical for the treatment of canine osteoarthritis. A double-blind, randomized, placebocontrolled prospective clinical trial. Vet Comp Orthop Traumatol. (2017) 30:318– 23. doi: 10.3415/VCOT-17-02-0020

18. Fernandez-Martin S, Gonzalez-Cantalapiedra A, Munoz F, Garcia-Gonzalez M, Permuy M, Lopez-Pena M. Glucosamine and chondroitin sulfate: is there any scientific evidence for their effectiveness as disease-modifying drugs in knee osteoarthritis preclinical studies?-A systematic review from 2000 to 2021. Animals. (2021) 11:1608. doi: 10.3390/ani11061608

20. Soontornvipart K, Mongkhon N, Nganvongpanit K, Kongtawelert P. Effect of PCSO-524 on OA biomarkers and weight-bearing properties in canine shoulder and coxofemeral osteoarthritis. Thai J Vet Med. (2015) 45:157–65.

21. Kwananocha I, Vijarnsorn M, Kashemsant N, Lekcharoensuk C. Effectiveness of disease modifying osteoarthritis agents and carprofen for treatment of canine osteoarthritis. Thai J Vet Med. (2016) 46:363–71

22. Vijarnsorn M, Kwananocha I, Kashemsant N, Jarudecha T, Lekcharoensuk C, Beale B, et al. The effectiveness of marine based fatty acid compound (PCSO524) and firocoxib in the treatment of canine osteoarthritis. BMC Vet Res. (2019) 15:349. doi: 10.1186/s12917-019-2110-7

23. Suzuki Y, Fukushima M, Sakuraba K, Sawaki K, Sekigawa K. Krill oil improves mild knee joint pain: a randomized control trial. PLoS ONE. (2016) 11:e0162769. doi: 10.1371/journal.pone.0162769

24. Laflamme DP. Development and validation of a body condition score system for dogs. Canine Pract. (1997) 22:10–5.

25. Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research, 2nd ed. Boca Raton, FL: Chapman and Hall/CRC (2003). doi: 10.1201/9780203911341

26. Hercock CA, Pinchbeck G, Giejda A, Clegg PD, Innes JF. Validation of a clientbased clinical metrology instrument for the evaluation of canine elbow osteoarthritis. J Small Anim Pract. (2009) 50:266–71. doi: 10.1111/j.1748-5827.2009.00765.x

27. Hielm-Bjorkman AK, Rita H, Tulamo RM. Psychometric testing of the Helsinki chronic pain index by completion of a questionnaire in Finnish by owners of dogs with chronic signs of pain caused by osteoarthritis. Am J Vet Res. (2009) 70:727– 34. doi: 10.2460/ajvr.70.6.727

28. Brown DC, Boston RC, Farrar JT. Comparison of force plate gait analysis and owner assessment of pain using the Canine Brief Pain Inventory in dogs with osteoarthritis. J Vet Intern Med. (2013) 27:22–30. doi: 10.1111/jvim.12004

29. Moreau M, Lussier B, Ballaz L, Troncy E. Kinetic measurements of gait for osteoarthritis research in dogs and cats. Can Vet J. (2014) 55:1057–65.

30. Waxman AS, Robinson DA, Evans RB, Hulse DA, Innes JF, Conzemius MG. Relationship between objective and subjective assessment of limb function in normal dogs with an experimentally induced lameness. Vet Surg. (2008) 37:241– 6. doi: 10.1111/j.1532-950X.2008.00372.x

31. McLaughlin RM. Kinetic and kinematic gait analysis in dogs. Vet Clin North Am Small Anim Pract. (2001) 31:193–201. doi: 10.1016/S0195-5616(01)50045-5

32. Conzemius MG, Torres BT, Muir P, Evans R, Krotscheck U, Budsberg S. Best practices for measuring and reporting ground reaction forces in dogs. Vet Surg. (2022) 51:385–96. doi: 10.1111/vsu.13772

33. Conzemius MG, Evans RB. Caregiver placebo effect for dogs with lameness from osteoarthritis. J Am Vet Med Assoc. (2012) 241:1314–9. doi: 10.2460/javma.241.10.1314

34. Venator KP, Frye CW, Gamble LJ, Wakshlag JJ. Assessment of a single intraarticular stifle injection of pure platelet rich plasma on symmetry indices in dogs with unilateral or bilateral stifle osteoarthritis from long-term medically managed cranial cruciate ligament disease. Vet Med. (2020) 11:31–8. doi: 10.2147/VMRR.S238598

35. Chervier, C.; Cadore, J.L.; Rodriguez-Pineiro, M.I.; Deputte, B.L.; Chabanne, L. Causes of anaemia other than acute blood loss and their clinical significance in dogs. J. Small Anim. Pract. 2012, 53, 223–227. [Google Scholar] [CrossRef] [PubMed]

36. Borchert, C.; Herman, A.; Roth, M.; Brooks, A.C.; Friedenberg, S.G. RNA sequencing of whole blood in dogs with primary immune-mediated hemolytic anemia (IMHA) reveals novel insights into disease pathogenesis. PLoS ONE 2020, 15, e0240975. [Google Scholar] [CrossRef]

37. Balch, A.; Mackin, A. Canine immune-mediated hemolytic anemia: Pathophysiology, clinical signs, and diagnosis. Compend. Contin. Educ. Vet. 2007, 29, 217–225. [Google Scholar] [PubMed]

38. Morley, P.; Mathes, M.; Guth, A.; Dow, S. Anti-erythrocyte antibodies and disease associations in anemic and nonanemic dogs. J. Vet. Intern. Med. 2008, 22, 886–892. [Google Scholar] [CrossRef] [PubMed]

39. Kjelgaard-Hansen, M.; Goggs, R.; Wiinberg, B.; Chan, D.L. Use of serum concentrations of interleukin-18 and monocyte chemoattractant protein-1 as prognostic indicators in primary immune-mediated hemolytic anemia in dogs. J. Vet. Intern. Med. 2011, 25, 76–82. [Google Scholar] [CrossRef] [PubMed]

40. Cuq, B.; Blois, S.L.; Bedard, C.; Wood, R.D.; Abrams-Ogg, A.C.; Beauchamp, G.; Wood, G.A. Serum interleukin 17 concentrations in dogs with immune-mediated hemolytic anemia. J. Vet. Intern. Med. 2021, 35, 217–225. [Google Scholar] [CrossRef]

41. Archer, T.M.; Mulligan, C.; Narayanan, L.; Riggs, C.; Fellman, C.; Thomason, J.M.; Wills, R.W.; Boothe, D.M.; Cruz-Espindola, C.; Harmon, R.; et al. Effects of oral administration of 5 immunosuppressive agents on activated T-cell cytokine expression in healthy dogs. J. Vet. Intern. Med. 2020, 34, 1206–1213. [Google Scholar] [CrossRef][Green Version]

42. Swann, J.W.; Skelly, B.J. Systematic review of evidence relating to the treatment of immune-mediated hemolytic anemia in dogs. J. Vet. Intern. Med. 2013, 27, 1–9. [Google Scholar] [CrossRef]

43. Swann, J.W.; Skelly, B.J. Evaluation of immunosuppressive regimens for immune-mediated haemolytic anaemia: A retrospective study of 42 dogs. J. Small Anim. Pract. 2011, 52, 353–358. [Google Scholar] [CrossRef]

44. Swann, J.W.; Garden, O.A.; Fellman, C.L.; Glanemann, B.; Goggs, R.; LeVine, D.N.; Mackin, A.J.; Whitley, N.T. ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs. J. Vet. Intern. Med. 2019, 33, 1141–1172. [Google Scholar] [CrossRef][Green Version]

45. Wolyniak, C.J.; Brenna, J.T.; Murphy, K.J.; Sinclair, A.J. Gas chromatography-chemical ionization-mass spectrometric fatty acid analysis of a commercial supercritical carbon dioxide lipid extract from New Zealand green-lipped mussel (Perna canaliculus). Lipids 2005, 40, 355–360. [Google Scholar] [CrossRef]

46. Doggrell, S.A. Lyprinol-is it a useful anti-inflammatory agent? Evid. Based Complement. Altern. Med. 2011, 2011, 307121. [Google Scholar] [CrossRef][Green Version]

47. Vijarnsorn, M.; Kwananocha, I.; Kashemsant, N.; Jarudecha, T.; Lekcharoensuk, C.; Beale, B.; Peirone, B.; Lascelles, B.D.X. The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis. BMC Vet. Res. 2019, 15, 349. [Google Scholar] [CrossRef][Green Version]

48. Mongkon, N.; Soontornvipart, K. Preliminary Study of the Clinical Outcome of Using PCSO-524 Polyunsaturated Fatty Acid Compound in the Treatment of Canine Osteoarthritis and Degenerative Spinal Diseases. Thai J. Vet. Med. 2013, 42, 311–317. [Google Scholar]

49. Kongwut, S.; Soontornvipart, K.; Sarikaphuti, M.; Makoom, P.; Nganvongpanit, K. Effect of Serum IL-1beta of PCSO-524 and Firocoxib in Dogs Undergoing Medial Patellar Luxation Repair. Thai J. Vet. Med. 2015, 45, 639–643. [Google Scholar]

50. Garden, O.A.; Kidd, L.; Mexas, A.M.; Chang, Y.M.; Jeffery, U.; Blois, S.L.; Fogle, J.E.; MacNeill, A.L.; Lubas, G.; Birkenheuer, A.; et al. ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats. J. Vet. Intern. Med. 2019, 33, 313–334. [Google Scholar] [CrossRef][Green Version]

51. Sun, P.L.; Jeffery, U. Effect of dilution of canine blood samples on the specificity of saline agglutination tests for immune-mediated hemolysis. J. Vet. Intern. Med. 2020, 34, 2374–2383. [Google Scholar] [CrossRef]

52. Paes, G.; Paepe, D.; Meyer, E.; Kristensen, A.T.; Duchateau, L.; Campos, M.; Daminet, S. The use of the rapid osmotic fragility test as an additional test to diagnose canine immune-mediated haemolytic anaemia. Acta Vet. Scand. 2013, 55, 74. [Google Scholar] [CrossRef][Green Version]

53. Baum, K.; Telford, R.D.; Cunningham, R.B. Marine oil dietary supplementation reduces delayed onset muscle soreness after a 30 km run. Open Access J. Sports Med. 2013, 4, 109–115. [Google Scholar] [CrossRef][Green Version]

54. Pumpa, K.L.; Fallon, K.E.; Bensoussan, A.; Papalia, S. The effects of Lyprinol((R)) on delayed onset muscle soreness and muscle damage in well trained athletes: A double-blind randomised controlled trial. Complement. Ther. Med. 2011, 19, 311–318. [Google Scholar] [CrossRef]

55. Liu, S.; Hu, W.; Fang, Y.; Cai, Y.; Zhang, J.; Liu, J.; Ding, Y. Extraction of oil from wet Antarctic krill (Euphausia superba) using a subcritical dimethyl ether method. RSC Adv. 2019, 9, 34274–34282. [Google Scholar] [CrossRef] [PubMed][Green Version]

56. Yin, F.-W.; Zhou, D.-Y.; Liu, Y.-F.; Zhao, Q.; Zhou, X.; Song, L.; Qi, H.; Zhu, B.-W. The Forms of Fluoride in Antarctic Krill (Euphausia superba) Oil Extracted with Hexane and its Removal with Different Absorbents. J. Aquat. Food Prod. Technol. 2017, 26, 835–842. [Google Scholar] [CrossRef]

57. Mickleborough, T.D.; Sinex, J.A.; Platt, D.; Chapman, R.F.; Hirt, M. The effects PCSO-524(R), a patented marine oil lipid and omega-3 PUFA blend derived from the New Zealand green lipped mussel (Perna canaliculus), on indirect markers of muscle damage and inflammation after muscle damaging exercise in untrained men: A randomized, placebo controlled trial. J. Int. Soc. Sports Nutr. 2015, 12, 10. [Google Scholar] [CrossRef] [PubMed][Green Version]

58. Piek, C.J.; Junius, G.; Dekker, A.; Schrauwen, E.; Slappendel, R.J.; Teske, E. Idiopathic immune-mediated hemolytic anemia: Treatment outcome and prognostic factors in 149 dogs. J. Vet. Intern. Med. 2008, 22, 366–373. [Google Scholar] [CrossRef] [PubMed]

59. Mistry, N.; Mazer, C.D.; Sled, J.G.; Lazarus, A.H.; Cahill, L.S.; Solish, M.; Zhou, Y.Q.; Romanova, N.; Hare, A.G.M.; Doctor, A.; et al. Red blood cell antibody-induced anemia causes differential degrees of tissue hypoxia in kidney and brain. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2018, 314, R611–R622. [Google Scholar] [CrossRef][Green Version]

60. Zoia, A.; Gerou-Ferriani, M.; Drigo, M.; Caldin, M. Case-control study of plasma mean platelet component concentration and survival analysis for dogs with immune-mediated hemolytic anemia. J. Am. Vet. Med. Assoc. 2018, 252, 1384–1392. [Google Scholar] [CrossRef]

61. Lawson, C.; Smith, S.A.; O’Brien, M.; McMichael, M. Neutrophil Extracellular Traps in Plasma from Dogs with Immune-mediated Hemolytic Anemia. J. Vet. Intern. Med. 2018, 32, 128–134. [Google Scholar] [CrossRef][Green Version]

62. Mektrirat, R.; Rueangsri, T.; Keeratichandacha, W.; Soonsawat, S.; Boonyapakorn, C.; Pongkan, W. Polyunsaturated Fatty Acid EAB-277((R)) Supplementation Improved Heart Rate Variability and Clinical Signs in Tracheal Collapse Dogs. Front. Vet. Sci. 2022, 9, 880952. [Google Scholar] [CrossRef]

63. Doganci, A.; Eigenbrod, T.; Krug, N.; De Sanctis, G.T.; Hausding, M.; Erpenbeck, V.J.; Haddad, E.B.; Lehr, H.A.; Schmitt, E.; Bopp, T.; et al. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J. Clin. Investig. 2005, 115, 313–325. [Google Scholar] [CrossRef][Green Version]

64. Valencia, X.; Stephens, G.; Goldbach-Mansky, R.; Wilson, M.; Shevach, E.M.; Lipsky, P.E. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006, 108, 253–261. [Google Scholar] [CrossRef]

65. Swann, J.W.; Woods, K.; Wu, Y.; Glanemann, B.; Garden, O.A. Characterisation of the Immunophenotype of Dogs with Primary Immune-Mediated Haemolytic Anaemia. PLoS ONE 2016, 11, e0168296. [Google Scholar] [CrossRef][Green Version]

66. Kampa, N.; Kaenkangploo, D.; Jitpean, S.; Srithunyarat, T.; Seesupa, S.; Hoisang, S.; Yongvanit, K.; Kamlangchai, P.; Tuchpramuk, P.; Lascelles, B.D.X. Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: A prospective, block-randomized, double-blinded, placebo-controlled clinical trial. Front. Vet. Sci. 2023, 10, 1033188. [Google Scholar] [CrossRef]

67. Swann, J.W.; Szladovits, B.; Threlfall, A.J.; Garden, O.A.; Chang, Y.M.; Church, D.B.; Glanemann, B. Randomised controlled trial of fractionated and unfractionated prednisolone regimens for dogs with immune-mediated haemolytic anaemia. Vet. Rec. 2019, 184, 771. [Google Scholar] [CrossRef]

68. Sri-Jayantha, L.S.; Doornink, M.T.; Urie, B.K. Increased risk of select glucocorticoid adverse events in dogs of higher body weight. Can. Vet. J. 2022, 63, 32–38. [Google Scholar]

69. Weingart, C.; Thielemann, D.; Kohn, B. Primary immune-mediated haemolytic anaemia: A retrospective long-term study in 61 dogs. Aust. Vet. J. 2019, 97, 483–489. [Google Scholar] [CrossRef]

70. Elkholly, D.A.; Brodbelt, D.C.; Church, D.B.; Pelligand, L.; Mwacalimba, K.; Wright, A.K.; O’Neill, D.G. Side Effects to Systemic Glucocorticoid Therapy in Dogs Under Primary Veterinary Care in the UK. Front. Vet. Sci. 2020, 7, 515. [Google Scholar] [CrossRef]

71. Swann, J.W.; Skelly, B.J. Canine autoimmune hemolytic anemia: Management challenges. Vet. Med. 2016, 7, 101–112. [Google Scholar] [CrossRef][Green Version]

72. Alvarez, A.M.; Mukherjee, D. Liver abnormalities in cardiac diseases and heart failure. Int. J. Angiol. 2011, 20, 135–142. [Google Scholar] [CrossRef][Green Version]

73. Jamikorn, U.; Yibchok-anun, S. Effects of Dietary Polyunsaturated Fatty Acid Supplement on Healthy Beagle Dogs. Thai J. Vet. Med. 2014, 44, 505–511. [Google Scholar]

74. Clarke DL. Interventional radiology management of tracheal and bronchial collapse. Vet Clin North Am Small Anim Pract. (2018) 48:765–79. doi: 10.1016/j.cvsm.2018.05.0102. Hedlund CS. Tracheal collapse. Probl Vet Med. (1991) 3:229–38. 3. Tappin SW. Canine tracheal collapse. J Small Anim Pract. (2016) 57:9–17. doi: 10.1111/jsap.12436

75. Hedlund CS. Tracheal collapse. Probl Vet Med. (1991) 3:229–38. 3.

76. Tappin SW. Canine tracheal collapse. J Small Anim Pract. (2016) 57:9–17. doi: 10.1111/jsap.12436

77. Maggiore AD. Tracheal and airway collapse in dogs. Vet Clin North Am Small Anim Pract. (2014) 44:117–27. doi: 10.1016/j.cvsm.2013.09.004

78. Papaioannou V, Pneumatikos I, Maglaveras N. Association of heart rate variability and inflammatory response in patients with cardiovascular diseases: current strengths and limitations. Front Physiol. (2013) 4:174. doi: 10.3389/fphys.2013.00174

79. Cooper TM, McKinley PS, Seeman TE, Choo TH, Lee S, Sloan RP. Heart rate variability predicts levels of inflammatory markers: evidence for the vagal anti-inflammatory pathway. Brain Behav Immun. (2015) 49:94–100. doi: 10.1016/j.bbi.2014.12.017

80. Yan M, Mehta JL, Zhang W, Hu C. LOX-1, oxidative stress and inflammation: a novel mechanism for diabetic cardiovascular complications. Cardiovasc Drugs Ther. (2011) 25:451–9. doi: 10.1007/s10557-011-6342-4

81. Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative stress and inflammation: what polyphenols can do for us? Oxid Med Cell Longev. (2016) 2016:7432797. doi: 10.1155/2016/7432797

82. Khoubnasabjafari M, Ansarin K, Jouyban A. Reliability of malondialdehyde as a biomarker of oxidative stress in psychological disorders. Bioimpacts. (2015) 5:123–7. doi: 10.15171/bi.2015.20

83. Cygankiewicz I, Zareba W. Heart rate variability. Handb Clin Neurol. (2013) 117:379–93. doi: 10.1016/B978-0-444-53491-0.00031-6

84. Chueainta P, Pongkan W, Boonyapakorn C. Clinical applications of heart rate variability in dogs. Vet Integr Sci. (2019) 17:195–220.

85. Lahdenoja O, Hurnanen T, Kaisti M, Koskinen J, Tuominen J, Vähä-Heikkilä M, et al. Cardiac monitoring of dogs via smartphone mechanocardiography: a feasibility study. Biomed Eng Online. (2019) 18:47. doi: 10.1186/s12938-019-0667-9

86. Thio CHL, van Roon AM, Lefrandt JD, Gansevoort RT, Snieder H. Heart rate variability and its relation to chronic kidney disease: results from the PREVEND study. Psychosom Med. (2018) 80:307–16. doi: 10.1097/PSY.0000000000000556

87. Chou YH, Huang WL, Chang CH, Yang CCH, Kuo TBJ, Lin SL, et al. Heart rate variability as a predictor of rapid renal function deterioration in chronic kidney disease patients. Nephrology. (2019) 24:806–13. doi: 10.1111/nep.13514

88. Serrao NF Jr., Porta A, Minatel V, Castro AAM, Catai AM, Sampaio LMM, et al. Complexity analysis of heart rate variability in chronic obstructive pulmonary disease: relationship with severity and symptoms. Clin Auton Res. (2020) 30:157–64. doi: 10.1007/s10286-019-00659-z

89. Li Y, Wang J, Li X, Jing W, Omorodion I, Liu L. Association between heart rate variability and Parkinson’s disease: a meta-analysis. Curr Pharm Des. (2021) 27:2056–67. doi: 10.2174/1871527319666200905122222 17. Lucini D, Pagani M. Heart rate variability, autonomic regulation and myocardial ischemia. Int J Cardiol. (2020) 312:22–3. doi:10.1016/j.ijcard.2020.03.012

90. Tan JPH, Beilharz JE, Vollmer-Conna U, Cvejic E. Heart rate variability as a marker of healthy ageing. Int J Cardiol. (2019) 275:101–3. doi: 10.1016/j.ijcard.2018.08.005

91. Alfonso A, Le Sueur ANV, Geraldes SS, Guimaraes-Okamoto PTC, Tsunemi MH, Santana DF, et al. Heart rate variability and electrocardiographic parameters predictive of arrhythmias in dogs with stage IV chronic kidney disease undergoing intermittent haemodialysis. Animals. (2020) 10:1829. doi: 10.3390/ani10101829

92. Petrie JP. Practical application of holter monitoring in dogs and cats. Clin Tech Small Anim Pract. (2005) 20:173–81. doi: 10.1053/j.ctsap.2005.05.00615

93. Hsieh BM, Beets AK. Coughing in small animal patients. Front Vet Sci. (2020) 6:513. doi: 10.3389/fvets.2019.00513

94. Williams J, editor. Management of tracheal collapse. World Small Animal Veterinary Association World Congress Proceedings. Cape Town (2014).

95. Della Maggiore A. An update on tracheal and airway collapse in dogs. Vet Clin North Am Small Anim Pract. (2020) 50:419–30. doi: 10.1016/j.cvsm.2019.11.003

96. Shei RJ, Adamic EM, Chapman RF, Mickleborough TD. The effects of PCSO524(R), a patented marine oil lipid derived from the New Zealand green lipped mussel (Perna canaliculus), on pulmonary and respiratory muscle function in non-asthmatic elite runners. Int J Exerc Sci. (2018) 11:669–80.

97. Vijarnsorn M, Kwananocha I, Kashemsant N, Jarudecha T, Lekcharoensuk C, Beale B, et al. The effectiveness of marine based fatty acid compound (PCSO524) and firocoxib in the treatment of canine osteoarthritis. BMC Vet Res. (2019) 15:349. doi: 10.1186/s12917-019-2110-7

98. Zhu B, Zhang Y, Herrup K. Testing the neuroprotective properties of PCSO524((R)) using a neuronal cell cycle suppression assay. Mar Drugs. (2019) 17:79. doi: 10.3390/md17020079

99. Mickleborough TD, Sinex JA, Platt D, Chapman RF, Hirt M. The effects PCSO-524(R), a patented marine oil lipid and omega-3 PUFA blend derived from the New Zealand green lipped mussel (Perna canaliculus), on indirect markers of muscle damage and inflammation after muscle damaging exercise in untrained men: a randomized, placebo controlled trial. J Int Soc Sports Nutr. (2015) 12:10. doi: 10.1186/s12970-015-0073-z

100. Doggrell SA. Lyprinol-is it a useful anti-inflammatory agent? Evid Based Complement Alternat Med. (2011) 2011:307121. doi: 10.1093/ecam/nep030

101. Mickleborough TD, Vaughn CL, Shei RJ, Davis EM, Wilhite DP. Marine lipid fraction PCSO-524 (lyprinol/omega XL) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma. Respir Med. (2013) 107:1152–63. doi: 10.1016/j.rmed.2013.04.010

102. Mongkon N, Soontornvipart K. Preliminary study of the clinical outcome of using PCSO-524 polyunsaturated fatty acid compound in the treatment of canine osteoarthritis and degenerative spinal diseases. Thai J Vet Med. (2012) 42:311–7. 31. Mateos R, Lecumberri E, Ramos S, Goya L, Bravo L. Determination of malondialdehyde (MDA) by high-performance liquid chromatography in serum and liver as a biomarker for oxidative stress: application to a rat model for hypercholesterolemia and evaluation of the effect of diets rich in phenolic antioxidants from fruits. J Chromatogr B Analyt Technol Biomed Life Sci. (2005) 827:76–82. doi: 10.1016/j.jchromb.2005.06.035

103. Pongkan W, Pintana H, Jaiwongkam T, Kredphoo S, Sivasinprasasn S, Chattipakorn SC, et al. Vildagliptin reduces cardiac ischemic-reperfusion injury in obese orchiectomized rats. J Endocrinol. (2016) 231:81–95. doi: 10.1530/JOE-16-0232 33. Pongkan W, Jitnapakarn W, Phetnoi W, Punyapornwithaya V, Boonyapakorn C. Obesity-induced heart rate variability impairment and decreased systolic function in obese male dogs. Animals. (2020) 10:1383. doi: 10.3390/ani10081383

104. Bogucki S, Noszczyk-Nowak A. Short-term heart rate variability (HRV) in healthy dogs. Pol J Vet Sci. (2015) 18:307–12. doi: 10.1515/pjvs-2015-0040 35. von Borell E, Langbein J, Despres G, Hansen S, Leterrier C, Marchant-Forde J, et al. Heart rate variability as a measure of autonomic regulation of cardiac activity for assessing stress and welfare in farm animals – a review. Physiol Behav. (2007) 92:293–316. doi: 10.1016/j.physbeh.2007.01.007

105. Lima AH, Forjaz CL, Silva GQ, Meneses AL, Silva AJ, Ritti-Dias RM. Acute effect of resistance exercise intensity in cardiac autonomic modulation after exercise. Arq Bras Cardiol. (2011) 96:498–503. doi: 10.1590/S0066-782X2011005000043

106. Latchman PL, Mathur M, Bartels MN, Axtell RS, De Meersman RE. Impaired autonomic function in normotensive obese children. Clin Auton Res. (2011) 21:319–23. doi: 10.1007/s10286-011-0116-8

107. Kenneth S, Edward A, Keith W. Duncan and Prasses’s Veterinary Laboratory Medicine Clinical Pathology. 4 ed. Ames, IA: Iowa State Press. (2003).

108. Regier PJ, Grosso FV, Stone HK, van Santen E. Radiographic tracheal dimensions in brachycephalic breeds before and after surgical treatment for brachycephalic airway syndrome. Can Vet J. (2020) 61:971–6.

109. Jepsen-Grant K, Pollard RE, Johnson LR. Vertebral heart scores in eight dog breeds. Vet Radiol Ultrasound. (2013) 54:3–8. doi: 10.1111/j.1740-8261.2012.01976.x

110. Vezzosi T, Puccinelli C, Tognetti R, Pelligra T, Citi S. Radiographic vertebral left atrial size: a reference interval study in healthy adult dogs. Vet Radiol Ultrasound. (2020) 61:507–11. doi: 10.1111/vru.12896

111. Zawadzki M, Janosch C, Szechinski J. Perna canaliculus lipid complex PCSO524 demonstrated pain relief for osteoarthritis patients benchmarked against fish oil, a randomized trial, without placebo control. Mar Drugs. (2013) 11:1920–35. doi: 10.3390/md11061920

112. Malik M. Producing consistent estimates of the power spectral density of NN sequences. Circulation. (1997) 96:2082–3.

113. Shukla RS, Aggarwal Y. Time-domain heart rate variability-based computer-aided prognosis of lung cancer. Indian J Cancer. (2018) 55:61–5. doi: 10.4103/ijc.IJC_395_17

114. Kleiger RE, Stein PK, Bigger JT Jr. Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol. (2005) 10:88–101. doi: 10.1111/j.1542-474X.2005.10101.x

115. Pongkan W, Pintana H, Sivasinprasasn S, Jaiwongkam T, Chattipakorn SC, Chattipakorn N. Testosterone deprivation accelerates cardiac dysfunction in obese male rats. J Endocrinol. (2016) 229:209–20. doi: 10.1530/JOE-16- 0002

116. Sivasinprasasn S, Sa-Nguanmoo P, Pongkan W, Pratchayasakul W, Chattipakorn SC, Chattipakorn N. Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats. Menopause. (2016) 23:894–902. doi: 10.1097/GME.00000000000 00640

117. Pavithran P, Nandeesha H, Sathiyapriya V, Bobby Z, Madanmohan T. Short-term heart variability and oxidative stress in newly diagnosed essential hypertension. Clin Exp Hypertens. (2008) 30:486–96. doi: 10.1080/10641960802251875

118. Pongkan W, Jinawong K, Pratchayasakul W, Jaiwongkam T, Kerdphoo S, Tokuda M, et al. D-allulose provides cardioprotective effect by attenuating cardiac mitochondrial dysfunction in obesity-induced insulin-resistant rats. Eur J Nutr. (2020). doi: 10.1007/s00394-020- 02394-y

119. Balasubramanian P, Asirvatham-Jeyaraj N, Monteiro R, Sivasubramanian MK, Hall D, Subramanian M. Obesity-induced sympathoexcitation is associated with Nrf2 dysfunction in the rostral ventrolateral medulla. Am J Physiol Regul Integr Comp Physiol. (2020) 318:R435–r44. doi: 10.1152/ ajpregu.00206.2019